Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02896816 · ClinicalTrials.gov registry record · NA

EMG Modules as a Novel Biomarker of Basal Ganglia Plasticity in Parkinson's Disease

A NA study, sponsored by Spaulding Rehabilitation Hospital.

Terminated
Registry status
NA
Development phase
17
Enrollment target

NCT02896816 is a NA study that was terminated before completion, run by Spaulding Rehabilitation Hospital. The registered enrollment target is 17 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02896816, a NA study, was terminated before completion, sponsored by Spaulding Rehabilitation Hospital.

TERMINATED
Registry status
NA
Development phase
17 participants
Enrollment target

Study Summary

Study Purpose: Parkinson's disease leads to severally impaired motor control. The purpose of this study is to better understand and analyze the characteristics of arm muscle activity while doing some reaching tasks and of leg muscles while walking. This will allow the investigators to improve understanding of the mechanisms underlying the motor impairments in Parkinson's disease.

Interventions

  • OTHER Surface EMG
  • OTHER Surface EMG, MRI and PET Scan

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2016-08
Est. Completion 2021-05-25
Phase NA

Sponsor

Spaulding Rehabilitation Hospital

101 total trials

What the Registry Record Tells You About NCT02896816

The ClinicalTrials.gov registry entry for NCT02896816 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spaulding Rehabilitation Hospital, which has 101 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Surface EMG is the first listed.

NCT02896816 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02896816 about?

NCT02896816 is a clinical study titled "EMG Modules as a Novel Biomarker of Basal Ganglia Plasticity in Parkinson's Disease". Study Purpose: Parkinson's disease leads to severally impaired motor control. The purpose of this study is to better understand and analyze the characteristics of arm muscle activity while doing some reaching tasks and of leg muscles while walking. This will allow the investigators to improve under...

What is the current status of trial NCT02896816?

This trial is currently terminated. It is a NA study. The enrollment target is 17 participants. The study started on 2016-08. Estimated completion is 2021-05-25.

What interventions are being tested in trial NCT02896816?

The interventions under investigation include: Surface EMG (OTHER), Surface EMG, MRI and PET Scan (OTHER).

Who is sponsoring clinical trial NCT02896816?

This trial is sponsored by Spaulding Rehabilitation Hospital, which has 101 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.